Poster Presentations: Wednesday, October 26, 2011 |

Linezolid for Treatment of Postviral Bacterial Pneumonia FREE TO VIEW

Urvashi Bhan, MD; Carol Wilke, MS; Megan Ballinger, PhD; Theodore Standiford, MD
Author and Funding Information

University of Michigan, Ann Arbor, MI

Chest. 2011;140(4_MeetingAbstracts):765A. doi:10.1378/chest.1112747
Text Size: A A A
Published online


PURPOSE: Bacterial pneumonia is a well described complication of influenza. In recent years, community-onset methicillin-resistant Staphylococcus aureus (cMRSA) infection has emerged as a contributor to morbidity and mortality in patients with influenza. Linezolid (LZD) is an oxazolidinone, the first new class of antibiotic developed in the last three decades. Although it is predominantly bacteriostatic, linezolid exhibits effective in-vitro and in-vivo activity against a wide variety of Gram-positive organisms, including methicillin susceptible S. aureus and methicillin-resistant S.aureus (MRSA). In this study we wanted to assess the effect of Linezolid on lung inflammatory response as well as lung injury in a murine model of post viral bacterial pneumonia as compared to Vancomycin (Vanco).

METHODS: Mice were infected with HINI strain of influenza and then challenged with cMRSA at day 7, treated with Abx at 6 hours and lungs harvested at 24 hours for bacterial clearance, inflammatory cell influx, cytokine/chemokines analysis and evidence of lung injury.

RESULTS: Mice treated with LZD or Vanco had significantly lower bacterial CFU in the lung with no systemic dissemination at 24 hours, though as compared to Vanco, mice treated with LZD had significantly lower number of neutrophils in the BAL (9x103 vs 2.3x104, p< 0.01) as compared to Vanco treated group. This was associated with significantly lower levels of proinflammatory cytokine TNF-α as well as chemokines KC, KE and IP-10. Interestingly, mice treated with LZD were protected from acute lung injury as measured by albumin leak in the BAL as compared to the Vanco treated group.

CONCLUSIONS: In conclusion, our study suggests that Linezolid has unique immunomodulatory effects on host inflammatory response and lung injury in a murine model of post-viral cMRSA pneumonia

CLINICAL IMPLICATIONS: LZD has immunomodulatory effects and protects against acute lung injury in post viral bacterial pneumonia

DISCLOSURE: Urvashi Bhan: University grant monies: ASPIRE grant

The following authors have nothing to disclose: Carol Wilke, Megan Ballinger, Theodore Standiford

No Product/Research Disclosure Information

09:00 AM - 10:00 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543